| 4.17 0.12 (2.96%) | 01-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.42 | 1-year : | 6.07 |
| Resists | First : | 4.64 | Second : | 5.19 |
| Pivot price | 4.13  |
|||
| Supports | First : | 3.74 | Second : | 3.11 |
| MAs | MA(5) : | 4.07 |
MA(20) : | 4.18 |
| MA(100) : | 5.31 |
MA(250) : | 5.08 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 33.8 |
D(3) : | 33.6 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 8.81 | Low : | 3.74 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DTIL ] has closed below upper band by 43.5%. Bollinger Bands are 63.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.22 - 4.23 | 4.23 - 4.24 |
| Low: | 3.91 - 3.93 | 3.93 - 3.94 |
| Close: | 4.14 - 4.17 | 4.17 - 4.2 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Mon, 29 Dec 2025
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL) - Seeking Alpha
Wed, 17 Dec 2025
Insider Buying: Stanley Frankel Acquires Additional Shares of Pr - GuruFocus
Tue, 11 Nov 2025
Precision BioSciences launches $75M stock and warrant offering - MSN
Tue, 11 Nov 2025
Latham Represents Precision BioSciences in US$75 Million Offering of Common Stock, Pre-Funded Warrants, and Warrants - Latham & Watkins LLP
Mon, 10 Nov 2025
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants - Business Wire
Mon, 03 Nov 2025
PRECISION BIOSCIENCES INC SEC 10-Q Report - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.256e+007 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 637 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.792e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -158 % |
| Return on Assets (ttm) | 976.9 % |
| Return on Equity (ttm) | -45.4 % |
| Qtrly Rev. Growth | 698000 % |
| Gross Profit (p.s.) | -81.42 |
| Sales Per Share | -170.97 |
| EBITDA (p.s.) | 581667 |
| Qtrly Earnings Growth | -9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 3.62 |
| Dividend | 0 |
| Forward Dividend | 1.11e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|